Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor αSu/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma

• Published in: Cancer research (Chicago, Ill.) Vol. 73; no. 10; pp. 3075 - 3086
• Main Authors: Xu, Wenxin, Jones, Monica, Liu, Bai, Zhu, Xiaoyun, Johnson, Christopher B., Edwards, Ana C., Kong, Lin, Jeng, Emily K., Han, Kaiping, Marcus, Warren D., Rubinstein, Mark P., Rhode, Peter R., Wong, Hing C.
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 15.05.2013
• Subjects: Animals; Antineoplastic agents; Antineoplastic Agents - therapeutic use; Biological and medical sciences; CD8-Positive T-Lymphocytes - immunology; Cell Line, Tumor; Cytotoxicity, Immunologic - drug effects; Female; Hematologic and hematopoietic diseases; Immunodeficiencies. Immunoglobulinopathies; Immunoglobulinopathies; Immunologic Memory; Immunopathology; Interferon-gamma - biosynthesis; Interleukin-15 - agonists; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Multiple Myeloma - drug therapy; Multiple Myeloma - immunology; Pharmacology. Drug treatments; Proteins - therapeutic use; Receptors, Interleukin-15 - therapeutic use; Tumors; Immunopathology; Animal model; Treatment efficiency; Rodentia; Cytokine; Malignant hemopathy; Interleukin 15 receptor; Interleukin 15; Myeloma; Vertebrata; Mammalia; Immunoglobulinopathy; Mouse; Lymphoproliferative syndrome; Syngeneic system; Mechanism of action; Cancer

ALT-803, a complex of an interleukin (IL)-15 superagonist mutant and a dimeric IL-15 receptor αSu/Fc fusion protein, was found to exhibit significantly stronger in vivo biologic activity on NK and T cells than IL-15. In this study, we show that a single dose of ALT-803, but not IL-15 alone, eliminat...